3,7‐Bis(2‐hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase‐5, prevents monocrotaline‐induced pulmonary arterial hypertension via NO/cGMP activation in rats

  title={3,7‐Bis(2‐hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase‐5, prevents monocrotaline‐induced pulmonary arterial hypertension via NO/cGMP activation in rats},
  author={Tao-Hua Lan and Xiao-ling Chen and Yun-Shan Wu and Huiliang Qiu and Jun-zhe Li and Xin-min Ruan and Dan Xu and Dongqun Lin},
  journal={European Journal of Pharmacology},
&NA; Pulmonary arterial hypertension (PAH) is a chronic progressive disease which leads to elevated pulmonary arterial pressure and right heart failure. 3,7‐Bis(2‐hydroxyethyl)icaritin (ICT), an icariin derivatives, was reported to have potent inhibitory activity on phosphodiesterase type 5 (PDE5) which plays a crucial role in the pathogenesis of PAH. The present study was designed to investigate the effects of ICT on monocrotaline (MCT)‐induced PAH rat model and reveal the underlying mechanism… Expand
DDCI-01, a novel long acting phospdiesterase-5 inhibitor, attenuated monocrotaline-induced pulmonary hypertension in rats
It is suggested that DDCI-01 improved monocrotaline-induced pulmonary hypertension in rats, and a dose of DDCi-01 of 9 mg/kg/day might be more effective than the same dose of tadalafil in monoc rotaline- induced pulmonary hypertensive rats. Expand
Protective Effects of 18β-Glycyrrhetinic Acid on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
Results of this study indicated that 18β-GA treatment significantly improved the hemodynamic and pathomorphological data of the rats, reduced the changes in oxidative stress biomarkers, and inhibited Nox2 and Nox4 expression. Expand
Magnesium lithospermate B ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and its potential targets.
The findings suggest that MLB ameliorates hypobaric hypoxia-induced PAH by inhibiting EndMT in rats, and has potential value in the preventment and treatment of PAH. Expand
Paclitaxel alleviates monocrotaline-induced pulmonary arterial hypertension via inhibition of FoxO1-mediated autophagy
Taking together, paclitaxel inhibits pulmonary vascular remodeling by FoxO1-mediated autophagy suppression, suggesting that pac litaxel might be a novel therapeutic agent for the prevention and treatment of PAH. Expand
Icariin ameliorates angiotensin II-induced cerebrovascular remodeling by inhibiting Nox2-containing NADPH oxidase activation
It is demonstrated that Icariin attenuates cerebrovascular SMCs hyperplasia and subsequent remodeling through inhibiting Nox2-containing NADPH oxidase activation, suggesting Icari in may be a potential therapeutic agent to prevent the onset and progression of stroke. Expand
Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma.
  • C. Bailly
  • Medicine, Biology
  • Chemico-biological interactions
  • 2020
An update of the pharmacological properties of ICT and its metabolic characteristics is provided and the design of derivatives, including both natural products and synthetic molecules, such as SNG1153 also in clinical trial are addressed. Expand
Secondary Metabolites of Plants as Modulators of Endothelium Functions
In this review, plants are summarized as sources of biologically active substances affecting the endothelium and individual substances and mechanisms that are known to affect the endot Helium, and which subsequently may cause the development of cardiovascular disorders. Expand


Icariin Inhibits Pulmonary Hypertension Induced by Monocrotaline through Enhancement of NO/cGMP Signaling Pathway in Rats
ICA is effective in protecting against MCT-induced PH in rats through enhancement of NO/cGMP signaling pathway in rats. Expand
Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling.
It is demonstrated that ICA treatments significantly improved learning and memory of APP/PS1 transgenic mice in Y-maze tasks and possibly through the stimulation of NO/cGMP signalling and co-ordinated induction of NOS isoforms. Expand
Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways
Liraglutide both prevented and reversed MCT-induced PAH, right ventricle hypertrophy and pulmonary vascular wall remodeling, and may have a therapeutic role in pulmonary vascular remodelling. Expand
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
Phosphodiesterase Type 5 is the main factor regulating cyclic guanosine monophosphate hydrolysis and downstream signaling in human PASMCs and the antiproliferative effects of this signaling pathway may be significant in the chronic treatment of pulmonary hypertension with PDE5 inhibitors such as sildenafil. Expand
Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro
Results indicate that tadalafil attenuates vascular remodeling by inhibiting cell proliferation, promoting apoptosis, and downregulating PDE5 in IPAH‐PASMCs, thereby ameliorating IPAH. Expand
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
Evidence shows that sildenafil is operative mainly in the vasculature of well-ventilated areas of the lung, and evidence shows that the PDE-5 inhibitor, despite oral application, displays characteristics of a pulmonary selective vasodilator. Expand
Genistein attenuates monocrotaline-induced pulmonary arterial hypertension in rats by activating PI3K/Akt/eNOS signaling.
It is confirmed that genistein could relax pulmonary vascular resistance, reduce pulmonary artery pressure, improve right heart function and ameliorate survival rate in the rat model of PAH and suggested that its mechanism was related with PI3K/Akt/eNOS signal pathway. Expand
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
Combination therapy of PDE-5 inhibitors with prostacyclin analogs and endothelin receptor antagonists may be helpful in the management of PAH although further studies are needed in this area. Expand
Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
TQ ameliorates MCT-induced pulmonary artery hypertension by inhibiting pulmonary arterial remodeling partially via p38MAPK/NF-κB signaling pathway in rats. Expand
Inhibition of Nuclear Factor-&kgr;B in the Lungs Prevents Monocrotaline-Induced Pulmonary Hypertension in Mice
It is concluded that NF-&kgr;B regulates bone morphogenetic protein receptor 2–inhibitor of differentiation–Notch-3 axis genes and the subsequent endothelial cell apoptosis and endothelial-to-mesenchymal transition events in the lungs, providing new mechanistic information about MCT-induced PAH and right ventricular hypertrophy. Expand